How to buy Renalytix AI stock

Renalytix AI plc is a diagnostics & research business based in the US. Renalytix AI shares (RNLX) are listed on the NASDAQ and all prices are listed in US Dollars. Renalytix AI employs 8 staff and has a trailing 12-month revenue of around 0.00.

Renalytix AI share price

Use our graph to track the performance of RNLX stocks over time.

Renalytix AI shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$9.91 - $32.12
50-day moving average	$27.03
200-day moving average	$19.38
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.26

Buy Renalytix AI shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Renalytix AI stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Renalytix AI plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Renalytix AI financials

Revenue TTM	$400,000
Gross profit TTM	$0
Return on assets TTM	-16.05%
Return on equity TTM	-23.63%
Profit margin	0%
Book value	N/A
Market capitalisation	$1.1 billion

TTM: trailing 12 months

Shorting Renalytix AI shares

There are currently 352,050 Renalytix AI shares held short by investors – that's known as Renalytix AI's "short interest". This figure is 14.1% up from 308,557 last month.

There are a few different ways that this level of interest in shorting Renalytix AI shares can be evaluated.

Renalytix AI's "short interest ratio" (SIR)

Renalytix AI's "short interest ratio" (SIR) is the quantity of Renalytix AI shares currently shorted divided by the average quantity of Renalytix AI shares traded daily (recently around 169254.80769231). Renalytix AI's SIR currently stands at 2.08. In other words for every 100,000 Renalytix AI shares traded daily on the market, roughly 2080 shares are currently held short.

However Renalytix AI's short interest can also be evaluated against the total number of Renalytix AI shares, or, against the total number of tradable Renalytix AI shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Renalytix AI's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Renalytix AI shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Renalytix AI shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Renalytix AI.

Find out more about how you can short Renalytix AI stock.

Renalytix AI share dividends

We're not expecting Renalytix AI to pay a dividend over the next 12 months.

Renalytix AI share price volatility

Over the last 12 months, Renalytix AI's shares have ranged in value from as little as $9.907 up to $32.12. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Renalytix AI's is 1.0474. This would suggest that Renalytix AI's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Renalytix AI overview

Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom. .

Frequently asked questions

What percentage of Renalytix AI is owned by institutions?
Currently 14.567% of Renalytix AI shares are held by institutions. How many people work for Renalytix AI?
Latest data suggests 8 work at Renalytix AI. When does the fiscal year end for Renalytix AI?
Renalytix AI's fiscal year ends in June. Where is Renalytix AI based?
Renalytix AI's address is: Avon House, Cardiff, United Kingdom, CF64 2EZ What is Renalytix AI's ISIN number?
Renalytix AI's international securities identification number is: US75973T1016